Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS

Objectives Transplant renal artery stenosis (TRAS) is now recognized as a curable disease with a good prognosis if intervention occurs in the early stage. However, the mid-term outcomes of TRAS when treated by percutaneous transluminal angioplasty with stent placement have yet to be fully elucidated...

Full description

Saved in:
Bibliographic Details
Main Authors: Long Zhang, Jilin Zou, Jiangqiao Zhou, Tao Qiu, Chenyang Kong, Tianyu Wang, Zhongbao Chen, Xiuheng Liu
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Renal Failure
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2024.2378211
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850140108001378304
author Long Zhang
Jilin Zou
Jiangqiao Zhou
Tao Qiu
Chenyang Kong
Tianyu Wang
Zhongbao Chen
Xiuheng Liu
author_facet Long Zhang
Jilin Zou
Jiangqiao Zhou
Tao Qiu
Chenyang Kong
Tianyu Wang
Zhongbao Chen
Xiuheng Liu
author_sort Long Zhang
collection DOAJ
description Objectives Transplant renal artery stenosis (TRAS) is now recognized as a curable disease with a good prognosis if intervention occurs in the early stage. However, the mid-term outcomes of TRAS when treated by percutaneous transluminal angioplasty with stent placement have yet to be fully elucidated. The purpose of this study was to compare mid-term graft and patient survival of TRAS group with a control group.Patients and methods Ninety-two patients were diagnosed of TRAS between January 2016 and January 2022 in our center. Fifty-six pairs of recipients with grafts from the same donor were selected as a study group with TRAS and a control group without TRAS, respectively. All donor kidneys were from deceased organ donation rather than living donors. The primary endpoints were graft and patient survival. The secondary outcomes were changes in renal graft function.Results The mean follow-up time for the TRAS group was 43.6 months, while the mean follow-up time for the control group was 45.3 months. In the TRAS group, the age of patients ranged from 11 to 62 years with 39 males and 17 females. In the control group, the age of patients ranged from 18 to 67 years with 40 males and 16 females. In the TRAS group, there were more patients with diabetic nephropathy as the primary renal disease compared to the control group (5/56 vs 0/56), and the incidence of acute rejection was higher in the TRAS group than in the control group (12/56 vs 3/56). Eight patients in the TRAS group and one patient in the control group experienced graft loss (p = .019). Four patients in the TRAS group and four patients in the control group died with functional renal allograft during the follow-up time (p = .989). The levels of eGFR did not differ significantly between the two groups in the first three years after kidney transplant (p > .05). Patients in the TRAS group had worse graft functionality (eGFR, 44.96 ± 18.9 vs 54.9 ± 19.6 mL/min) in the fourth year when compared with the control group (p = .01).Conclusions The graft function deteriorated faster, and graft survival was lower in the TRAS group treated by stent placement when compared with a control group without TRAS over the mid-term.
format Article
id doaj-art-33fc42dff812454d90259fcbcc2c934d
institution OA Journals
issn 0886-022X
1525-6049
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Renal Failure
spelling doaj-art-33fc42dff812454d90259fcbcc2c934d2025-08-20T02:29:56ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146210.1080/0886022X.2024.2378211Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRASLong Zhang0Jilin Zou1Jiangqiao Zhou2Tao Qiu3Chenyang Kong4Tianyu Wang5Zhongbao Chen6Xiuheng Liu7Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, ChinaObjectives Transplant renal artery stenosis (TRAS) is now recognized as a curable disease with a good prognosis if intervention occurs in the early stage. However, the mid-term outcomes of TRAS when treated by percutaneous transluminal angioplasty with stent placement have yet to be fully elucidated. The purpose of this study was to compare mid-term graft and patient survival of TRAS group with a control group.Patients and methods Ninety-two patients were diagnosed of TRAS between January 2016 and January 2022 in our center. Fifty-six pairs of recipients with grafts from the same donor were selected as a study group with TRAS and a control group without TRAS, respectively. All donor kidneys were from deceased organ donation rather than living donors. The primary endpoints were graft and patient survival. The secondary outcomes were changes in renal graft function.Results The mean follow-up time for the TRAS group was 43.6 months, while the mean follow-up time for the control group was 45.3 months. In the TRAS group, the age of patients ranged from 11 to 62 years with 39 males and 17 females. In the control group, the age of patients ranged from 18 to 67 years with 40 males and 16 females. In the TRAS group, there were more patients with diabetic nephropathy as the primary renal disease compared to the control group (5/56 vs 0/56), and the incidence of acute rejection was higher in the TRAS group than in the control group (12/56 vs 3/56). Eight patients in the TRAS group and one patient in the control group experienced graft loss (p = .019). Four patients in the TRAS group and four patients in the control group died with functional renal allograft during the follow-up time (p = .989). The levels of eGFR did not differ significantly between the two groups in the first three years after kidney transplant (p > .05). Patients in the TRAS group had worse graft functionality (eGFR, 44.96 ± 18.9 vs 54.9 ± 19.6 mL/min) in the fourth year when compared with the control group (p = .01).Conclusions The graft function deteriorated faster, and graft survival was lower in the TRAS group treated by stent placement when compared with a control group without TRAS over the mid-term.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2378211Transplant renal artery stenosiskidney transplantstent placementinterventional therapygraft survival
spellingShingle Long Zhang
Jilin Zou
Jiangqiao Zhou
Tao Qiu
Chenyang Kong
Tianyu Wang
Zhongbao Chen
Xiuheng Liu
Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
Renal Failure
Transplant renal artery stenosis
kidney transplant
stent placement
interventional therapy
graft survival
title Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
title_full Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
title_fullStr Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
title_full_unstemmed Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
title_short Graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis (TRAS) is worse compared to matched cadaveric grafts without TRAS
title_sort graft survival after percutaneous transluminal renal stenting for transplant renal artery stenosis tras is worse compared to matched cadaveric grafts without tras
topic Transplant renal artery stenosis
kidney transplant
stent placement
interventional therapy
graft survival
url https://www.tandfonline.com/doi/10.1080/0886022X.2024.2378211
work_keys_str_mv AT longzhang graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT jilinzou graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT jiangqiaozhou graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT taoqiu graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT chenyangkong graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT tianyuwang graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT zhongbaochen graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras
AT xiuhengliu graftsurvivalafterpercutaneoustransluminalrenalstentingfortransplantrenalarterystenosistrasisworsecomparedtomatchedcadavericgraftswithouttras